Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, pathologically, and clinically. Here, we describe a robust protocol for long-term culturing of human mammary epithelial organoids. Using this protocol, >100 primary and metastatic BC organoid lines were generated, broadly recapitulating the diversity of the disease. BC organoid morphologies typically matched the histopathology, hormone receptor status, and HER2 status of the original tumor. DNA copy number variations as well as sequence changes were consistent within tumor-organoid pairs and largely retained even after extended passaging. BC organoids furthermore populated all major gene-expression-based classification groups and allowed in vitro drug screens that were consistent with in vivo xeno-transplantations and patient response. This study describes a representative collection of well-characterized BC organoids available for cancer research and drug development, as well as a strategy to assess in vitro drug response in a personalized fashion.
The heterogeneity of breast cancer subtypes can be captured using organoid cultures that can facilitate drug screens that corroborate with patient responses.
INTRODUCTION
Breast cancer (BC) is the most frequently diagnosed cancer and cause of cancer death among women worldwide (Stewart and Wild, 2014) . BC comprises more than 20 distinct subtypes that differ genetically, morphologically, and clinically (Lakhani, 2012) . BC heterogeneity is best exemplified by next-generation sequencing studies that have drawn comprehensive molecular BC portraits (Cancer Genome Atlas, 2012; Ciriello et al., 2015) and identified more than 1,600 likely driver mutations in 93 BC genes (Nik-Zainal et al., 2016) . Despite the increased understanding of BC complexity, therapeutic approaches are currently largely based on clinical and pathological BC features, supplemented by hormone receptor and human epidermal growth factor receptor 2 (HER2) status (Lakhani, 2012) . Consequently, the present standard systemic therapies (hormone, cytotoxic, and HER2-targeted) are unsatisfactorily tailored to individual patients. In response, rationally chosen targeted therapies are being evaluated in clinical trials (Zardavas et al., 2013) , with individualized therapy being the final goal. Identifying unique molecular tumor features alone, however, can only guide treatment and will fail to predict clinical results without functional validation. Vice versa, functionally testing BC remedies in vitro could predict patient outcome even without molecular knowledge.
To functionally complement molecular and pathological BC analysis, representative and robust BC models are required that can be generated efficiently. The most prevalent humanderived BC models to date are cell lines (Holliday and Speirs, 2011) and patient-derived xenografts (PDX) (Whittle et al., 2015) . Although both model systems have contributed tremendously to translational BC research, they also have drawbacks (Vargo-Gogola and Rosen, 2007) . Derivation of cell lines as well as PDXs is inefficient, labor-intensive, and requires multiple months per case, making it virtually impossible for them to contribute to individualized therapy on a broad scale. In addition, both models are usually derived from advanced-stage tumors and consequently do not fully capture the BC spectrum.
Inspired by three-dimensional cell culture systems of the mammary epithelium (Lee et al., 2007; Shaw et al., 2004) , we established culture protocols that allow the generation and longterm expansion of three-dimensional epithelial organoids (Sato and Clevers, 2015; Sato et al., 2009) . In contrast to the simultaneously developed culture method by Ootani et al. (2009) , our adult stem cell-based cultures lack mesenchymal cells and generally require the following niche factors: the mitogen epidermal growth factor (EGF), the Wnt-agonist R-spondin, the transforming growth factor beta (TGF-b) inhibitor Noggin, and the extracellular matrix surrogate basement membrane extract (BME, or Matrigel). Depending on species and organ, additional common additives are among others (a.o.) Wnt-3A and fibroblast growth factor (FGF) 10, the activin receptor-like kinase (ALK) inhibitor A83-01, the p38 mitogen-activated protein kinase inhibitor SB202190, and the vitamin nicotinamide (Sato and Clevers, 2015) . Organoids can be established from healthy as well as diseased donors (including cancer) and recapitulate the epithelial architecture and physiology of the organs they were isolated from (Clevers, 2016) . We and others have successfully generated organoids from primary colon, prostate, and pancreatic cancers (Boj et al., 2015; Fujii et al., 2016; Gao et al., 2014; Sato et al., 2011; van de Wetering et al., 2015) and explored the potential advantages of organoid cultures in allowing functional tests and genotype-phenotype correlations (Neal and Kuo, 2016; Sachs and Clevers, 2014) . Here, we describe efficient protocols for the culture of BC organoids and establish a representative collection of well-characterized BC organoids for BC research and drug discovery.
RESULTS

Establishing a Living BC Organoid Biobank
We obtained BC tissue from patients that underwent lumpectomy under informed consent (Table S1) , removed normal tissue, and isolated BC cells through a combination of mechanical disruption and enzymatic digestion (see the STAR Methods). Isolated cells were plated in adherent BME drops and overlaid with optimized BC organoid culture medium ( Figure 1A ; Table S2) . A key addition, compared to previously established human organoid protocols (Sato and Clevers, 2015; Sato et al., 2011) , was the mitogen Neuregulin 1. Neuregulin 1 is a ligand of human EGF receptor (HER) tyrosine kinases -3 and -4 and has been implicated in mammary development as well as tumorigenesis (Roskoski, 2014; Troyer and Lee, 2001; Wansbury et al., 2008; Yang et al., 1995) . Its addition to BC organoid medium allowed the efficient generation of BC organoids as well as their longterm expansion for >20 passages. Inhibition of Rho-associated coiled-coil containing protein kinase (ROCK) has been shown to allow long-term proliferation of tumor epithelial cells in vitro (Liu et al., 2012) and addition of the specific ROCK inhibitor Y-27632 indeed improved culture conditions. During medium optimization we furthermore noted that (1) addition of Wnt-3A did not improve culture conditions notably, (2) EGF concentrations above 5 ng 3 ml À1 increased proliferation, but caused BC organoids to gradually sink through BME and lose their threedimensional organization, and (3) SB202190 concentrations above 1 mM decreased efficiency of organoid establishment. From 155 tumors, we established 95 BC organoid lines that readily expanded. Importantly, we did not observe a bias of organoid establishment with respect to histological subtype, grading, or receptor status of the original BC ( Figure 1B ; Table  S1 ). Organoid lines could not always be established due to imperfect sampling and less effective earlier versions of the organoid medium. Following this learning-by-doing phase, we improved the success rate of BC organoid establishment to currently >80% and cryopreserved the majority of BC organoid lines (Table S1 ). While normal organoids consistently displayed a cystic phenotype, individual BC organoid lines differed greatly in their morphology as observed by bright-field microscopy. For example, we observed solid organoids of different sizes, cystic organoids, ''grape-like'' organoids, and organoids that were almost completely discohesive ( Figure 1C ; Movie S1). In order to generate a well-annotated living biobank as resource for academic research and drug discovery, we next set out to analyze BC organoids in depth by means of histology, whole genome DNA sequencing (WGS), RNA sequencing (RNA-seq), and drug testing ( Figure 1D ). In the following paragraphs, we describe the results of our ongoing effort to characterize the first set of BC organoids. All current and future BC organoid lines will be equally characterized, annotated, and made available on request as part of the HUB Living Biobank following approval by the internal review board of the University Medical Center Utrecht (METC-UMCU) ( Figure 1D ; see the STAR Methods).
Histological Characterization of BC Organoids
For decades, BC has been classified into meaningful subgroups based on histological features (Azzopardi et al., 1979; Ellis et al., 1992; Elston and Ellis, 1991; Lakhani, 2012) . Together with receptor status, histological grading and typing helps to describe distinct clinical presentations, suggest intervention strategies, and estimate survival rates (Lakhani, 2012) . The most prevalent histological subtypes of BC are invasive ductal carcinoma of no special type (50%-80%) and invasive lobular carcinoma (5%-15%) (Lakhani, 2012) . Our BC panel and derived BC organoids show a similar distribution ( Figure 1B ; Table S1 ). To test whether BC organoids match the original histological BC type, we performed blinded histopathological analysis of H&E stained tissue and organoid sections. The phenotype of BC organoid often agreed with the original BC (Figure 2 ; Table S3 ). For example, ductal carcinoma generally gave rise to solid, coherent organoids, while lobular carcinoma mainly generated discohesive organoids (Figure 2 ; Table S3 ). In addition, the majority of BC organoids was judged clearly malignant (Table S3) based on cellular and nuclear atypia. We, for example, regularly encountered typical cancerous features such as enlarged and polymorphic nuclei, high mitotic activity, apoptosis, and vacuole formation (signet ring cells) ( Figure S1 ; Table S3 ). In contrast, control organoids established from histologically normal preventive mastectomy (PM) samples were very well organized and displayed only a mildly complex cribriform architecture ( Figure S1 ) resembling benign ductal hyperplasia in vivo. PM organoids did not show cellular or nuclear atypia and were histologically judged to represent normal breast epithelium or ductal hyperplasia ( Figure S1 ; Table S3 ).
Besides histological conservation, a representative BC model should retain expression of the most important and prevalent breast cancer biomarkers: estrogen receptor (ER), progesterone receptor (PR), and HER2. The status of hormone receptors ER and PR has predictive value for the outcome of hormone/endocrine BC therapy, while HER2 status can predict systemic chemotherapy outcome and in itself is a target for cancer therapies (Brennan and Lim, 2015; Dai et al., 2016) . We indeed found hormone receptor and HER2 status to be maintained in the majority of BC tissue-organoid pairs as determined by immunohistochemistry. Tumors positive for ER and/or PR gave rise to ER-and/or PR-positive BC organoids in $75% of cases. ERand/or PR-negative tumors generated >90% ER-and/or PRnegative BC organoids. HER2 status was retained in 80% of HER2 positive and >90% of HER2 negative BC tissue-organoid pairs (Figures 2 and S1 ; Table S3 ).
In summary, we found that the majority of BC organoids matches the originating BC with respect to histopathology as well as hormone and HER2 receptor status. However, the histological analysis did not unequivocally assign tumor status to all BC organoids, with several lines being classified as either welldifferentiated tumor or normal epithelium (Table S3) . Thus, histological analysis can detect clear malignant morphological features of organoids from e.g., poorly differentiated tumors, yet it may fail to accurately categorize well-differentiated BC organoids, especially out of tissue-context.
Genomic Characterization of BC Organoids
Whereas histological analysis benefits from stromal and inflammatory cells in tumor tissue, these cell populations impede Table S2 ). (B) Pie charts comparing the stratification of all tumors with that of all derived organoid lines based on histological type (top), grade (middle), and receptor status (bottom). The composition of BC organoid lines is indistinguishable from that of the original tumors in all three categories, indicating that organoids can be established without bias from all BCs (see Table S1 ). (C) Bright-field images depicting major BC organoid phenotypes. The top row shows cohesive organoids (left and middle: dense and solid; right: cystic and hollow), while the bottom row shows increasingly discohesive organoids (from left to right). Scale bar, 100 mm. See also Movie S1. (D) Workflow summarizing the characterization of BC organoids by microscopy, DNA-sequencing, RNA-sequencing, and drug response, as well as their biobanking and subsequent distribution to academic or pharmaceutical third parties following ethical approval. (Danielsen et al., 2016) , we first karyotyped BC organoids in order to verify their histologically assigned malignant status. We indeed found BC-characteristic chromosome number changes including frequent hyperdiploidies and occasional hypodiploidies ( Figure 3A) . We next employed WGS (STAR Methods) as current gold standard (Nik-Zainal et al., 2016) to characterize BC genomes including copy number alterations (CNAs) and somatic mutations. Per patient, we sequenced genomic DNA (gDNA) isolated from normal blood, BC tissue, and BC organoids ( Figure S2A ). In light of commonly misidentified and cross-contaminated cell lines (Lorsch et al., 2014) , we first mapped genetic distances between all samples to verify the identity of each BC organoid line. Although the vast majority of patient-specific DNA samples indeed clustered together, we identified one case of swapped blood DNA samples as well as two cases of cross-contamination ( Figure S2B ), emphasizing the need for rigorous quality control. The latter cases were excluded from further analysis and additional organoid culture rules implemented to minimize future risk of crosscontamination (STAR Methods).
CNAs generally affect a large portion of the BC genome and include driver as well as passenger events (Pereira et al., 2016; Zack et al., 2013) . Therefore, we first compared genome-wide CNAs of BCs and the corresponding BC organoids and as expected found multiple chromosome rearrangements including chromothripsis ( Figure S3A ; Table S3 ). DNA copy number gains and losses were retained throughout genomes ( Figure 3B ; Table  S3 ) with BC organoids often showing much cleaner and more distinct copy number signals than original BCs. Importantly, these CNAs were largely retained even after extended passaging ( Figure S3A ). Next, we selected cancer genes exhibiting significant CNAs in breast cancer (Cancer Genome Atlas, 2012; Zack et al., 2013 ) and compared the respective CNA profiles of BCs with derived organoids. BC organoids recapitulated the original CNA patterns of cancer genes and generally showed a higher signal amplitude ( Figure 3C ) similarly to genome-wide CNAs ( Figure 3B ). Examples of specific BC genes whose CNAs were retained across several tumor-organoid pairs include CDKN2A, ERBB2, NF1, and SNX31 ( Figure 3C ).
Cancers invariably accumulate somatic mutations that, depending on the affected gene(s), can drive cancer progression (Martincorena and Campbell, 2015) . Driver as well as passenger mutations arise through diverse mutational processes resulting in distinct mutational signatures, at least 12 of which are found in BC (Alexandrov et al., 2013; Nik-Zainal et al., 2012 . We mathematically analyzed base substitutions in BCs and organoids and plotted the total number of mutations per mutational signature per patient ( Figure 4A ). Not surprisingly, the total number of mutations as well as the relative contribution of individual signatures greatly differed between patients. For example, we found two hypermutated samples with more than 20,000 mutations. We furthermore identified significant contributions of all major BC signatures, including kataegis and BRCA-deficiency signatures (Figures 4A and 4B) . In contrast to interpatient heterogeneity, mutation loads and types were mostly conserved in matching BC-organoid pairs (Figures 4A-4C; Table S4 ). Importantly, BC organoids displayed mutations in many of the most relevant BC genes (Banerji et al., 2012; Cancer Genome Atlas, 2012; Nik-Zainal et al., 2016; Pereira et al., 2016) . For example, we found inactivating mutations in tumor suppressors TP53 and CDH1, as well as MLL2/3 epigenetic complexes and activating mutations in the oncogene PIK3CA ( Figure 4D ), most of which are conserved between BC-organoid pairs. In summary, we show that BC organoids recapitulate the diverse genomic landscape of BC including CNAs, mutational load and signatures, as well as cancer gene mutations.
Gene Expression Analysis of BC Organoids and Gene Editing
Gene expression profiling contributed significantly to subcategorizing BC with several gene sets and analysis algorithms being used clinically (Schmidt et al., 2016) . We therefore compared gene expression of normal and BC organoids by performing RNA-seq on 22 lines and assembling a correlation heatmap based on >25,000 genes. As shown in Figure 5A , normal organoids hierarchically clustered together with a subset of five BC organoid lines. The remaining 15 BC organoid lines clustered separately and were considerably more heterogeneous. When combining organoid expression data with >1,100 BC expression data from The Cancer Genome Atlas (TCGA) we found BC organoids to populate all major subclusters and distribute randomly throughout the dataset ( Figure 5B ). Multiple RNA expressionbased BC classification systems have been proposed: PAM50, SCMGENE, SCMOD1, and IntClust Desmedt et al., 2008; Haibe-Kains et al., 2012; Parker et al., 2009 ) with the first three classifiers mainly relating to receptor status. Organoids can be found in all subtypes with basal, luminal A, and normal subtypes dominating PAM50, and ER À /HER2 À and HER + subtypes dominating SCMGENE/SCMOD1 classifiers. IntClust, a 10 subtype classifier that additionally considers copy numbers, has organoids present in 7 subtypes with category iC4 containing most organoid lines. Subtype assignment reflects known subtype correspondence, namely iC10 with triple negative samples and iC5 with HER2 + . When comparing the expression profiles of discohesive versus solid BC organoids (Figure 2 ), we found expression differences in cell adhesion genes to be statistically overrepresented (Table S6 ). The resulting gene lists also included genes previously not implicated in BC cell adhesion (e.g., polymeric immunoglobulin receptor and protocadherins beta-16 and gamma b4). BC organoids therefore display representative gene expression profiles, which allow hierarchical clustering into the majority of RNA expression-based BC subtypes without a significant culture bias, and aid the characterization of epithelial cell biological phenomena. To test if mammary gland organoids can be experimentally manipulated, we generated functional TP53 mutant clones through CRISPR/ Cas9-mediated gene editing ( Figure S4 ).
Drug Screen
In order to evaluate BC organoids as functional in vitro disease models, we tested whether BC organoids could be used for high-throughput drug sensitivity screens. We chose a small set of drugs targeting the HER signaling pathway ( Figure 6A ) and performed cell viability assays as described for colorectal cancer (CRC) organoids (van de Wetering et al., 2015) . Using 21 concentrations per drug we were able to generate reproducible doseresponse curves and identify half-maximal inhibitory concentrations (IC 50 ) (Figures 6B and 6C) . In the majority of cases, we found a homogeneous response to a certain drug yielding Figure 4C and Table S4 ). 28T and 86T show >20,000 mutations mainly belonging to signatures 2 and 13, which are commonly found in locally hypermutated BCs (kataegis) and associated with AID/APOBEC enzymes.
(legend continued on next page) a single IC 50 . However, we sometimes found several relative IC 50 values, indicating the presence of differentially susceptible organoid subpopulations ( Figure 6B ). Overall, organoids were sensiSignature 3, which is strongly associated with BRCA1 and BRCA2 mutations, accounts for a high percentage of mutations in multiple samples including 10T, 13T, 22T, and 27T. (B) Bar graphs showing the relative contributions of point mutation types underlying mutational signatures for selected cases. Mutation types differ greatly between patients, but are conserved among matching tissue/organoid pairs. (C) Box-and-whisker plot showing the correlation percentages of mutational spectra of tissue/organoid pairs (see also Table S4 ). (D) Overview of somatic mutations found in BC genes of BC-organoid pairs grouped per patient (T, tissue; O, organoid). Shown is the most severe mutation per gene, examples include missense mutations (e.g., AHNAK, MLL2, and MUC16) and nonsense, splice site mutations as well as frameshift indels (e.g., CDH1 and TP53). (A) Correlation heatmap of BC organoids and organoids derived from preventive mastectomies (128 PM I and II). The 22 organoid RNA-seq samples were normalized for sequencing depth (see STAR Methods), log 2 -transformed, and meancentered by genes (rows). Spearman correlations were calculated for all sample-pairs, using all 25,991 genes. The heatmap shows clustering of samples by 1-correlation distance using complete linkage for hierarchical clustering. Cells are colorcoded by the Spearman correlation value. (B) Organoid RNA-seq data (22 samples) was normalized and combined with TCGA RNA-seq data (1,102 samples, see STAR Methods). The combined data were clustered using the 500 most varying genes using 1-correlation distance with complete linkage. The distribution of organoid samples among TCGA data is indicated by black lines. Annotation rows show ER, PR, and HER2 status determined by staining, followed by subtype assignments according to PAM50, SCMGENE, SCMOD1, and IntClust classifiers (for details see Table S5 ).
tive to drugs blocking the HER signaling pathway, when they overexpressed HER2 and drug-resistant in the absence of HER2. However, a few organoid lines defied these expectations ( Figure 6B ), emphasizing the value of functional in vitro drug tests on BC organoids. Poly(ADP-ribose)polymerase inhibitors (PARPis) are successfully being used in BC patients with defective BRCA-mediated genome repair pathways (Lee et al., 2014) . We subjected BC organoid lines with the highest and lowest relative contributions of mutant BRCA1/2 signatures to increasing concentrations of the PARPis olaparib and niraparib and assessed cell viability as above. While BC organoids with high BRCA1/2 signatures were sensitive to PARPi, BC organoids with low BRCA1/2 signatures were not ( Figure 6C ). Of note, line 10T did not show BRCA1/2 mutations despite high BRCA1/2 signatures, highlighting the advantage of WGS in combination with functional drug screens on BC organoids.
Comparison to Drug Response In Vivo
To compare in vitro with in vivo drug responses, we first selected two BC organoid lines that responded differently to drugs blocking HER signaling in vitro ( Figure 7A ) and transplanted each line orthotopically into both flanks of 10 mice. Once a tumor grew larger than 50 mm 3 , the respective mouse was either treated with 10 mg/g bodyweight afatinib or with vehicle for 28 days ( Figure 7B ). Tumors originating from afatinib-resistant BC organoid line 27T grew at virtually the same rates when treated with afatinib or vehicle ( Figure 7B ). In contrast, tumors originating from afatinib-sensitive line 10T grew significantly slower when treated with afatinib compared to vehicle ( Figure 7B ). Consequently, mice carrying 27T tumors had to be sacrificed at the same time irrespective of treatment type, while mice carrying 10T tumors lived significantly longer when given afatinib compared to vehicle ( Figure 7B ) recapitulating the respective in vitro drug response. Because the established BC organoid lines were derived from surgically removed BCs, we were unable to correlate in vitro drug response directly to patient responses. We therefore generated 12 BC organoid lines from needle biopsies of 13 patients with metastatic BC (Table S1 ). Patients were given standard of care treatment and responses recorded (Table S1 ). Tamoxifen was the only drug that resulted in differential responses in our limited metastatic BC set (Table S1 ) with one patient being responsive, one non-responsive, and the remainder undetermined. In vitro responses of the BC organoids to tamoxifen matched that of the respective patients ( Figure 7C ) indicating the potential use of BC organoids as predictive in vitro surrogates for BC in vivo. Table S1 ) and compared to in vitro response of the respectively derived BC organoids (dose-response curve on
(legend continued on next page)
In summary, BC organoids can be generated efficiently from all major BC subtypes. BC organoids capture and retain histological as well as genetic BC heterogeneity and allow physiologically relevant in vitro drug screens.
DISCUSSION
For decades, pre-clinical BC research has relied on a few dozens of cell lines as in vitro representations of a heterogeneous disease affecting millions of patients. While amenable to highthroughput screening, BC cell lines do not fully capture the BC spectrum and are rarely of clinical relevance for individual patients (Sharma et al., 2010) . PDX models, as the other pillar of pre-clinical BC research, capture tumor heterogeneity, but traditionally have not allowed for high-throughput screening. Recently, several groups tackled this problem by directly treating mice in vivo (Gao et al., 2015) or PDX-derived cultures in vitro (Bruna et al., 2016) . Although very promising, both methods still depend on inefficient PDX generation and the latter does not allow extended passaging in vitro.
By adapting previously published organoid protocols (Sato and Clevers, 2015), we overcame both hurdles with the addition of Neuregulin 1 allowing both the efficient generation and longterm maintenance of BC organoids. Because BC organoids recapitulate central BC features, they may represent a third pre-clinical BC model in between 2D cell lines in vitro and PDX models in vivo. The first striking feature of BC organoids is their phenotypic diversity that appears to reflect BC histology: while ductal BCs usually give rise to solid organoids, lobular BCs most often generate discohesive organoids. Lobular histology appears to correlate with poor survival when adjusted for other patient parameters (Korhonen et al., 2013) . Discohesive BC organoids could be a unique experimental tool to better understand the underlying mechanisms of lobular histology and identify potential drug targets. While we, for example, identify loss of E-cadherin function in a subset of discohesive BC organoids (28T, 66T, and 74T) as expected (Christgen et al., 2016) , other organoids await a molecular explanation. Because mammary gland organoids lend themselves to gene editing, phenotypic screens can easily be performed and hypotheses tested. The second central feature of BC organoids is the advantage to extract genetic data from pure tumor epithelium. The absence of ''contaminating'' genetically normal cell types allows for much cleaner CNA profiles as well as easier detection of somatic mutations. The same holds true for gene expression analysis, where expression-based subtypes could clearly be assigned to the majority of BC organoids and the cause of biological phenomena such as epithelial cell adhesion be interrogated. However, the absent tumor environment in vitro may cause differences between expression profiles of tumor-organoid pairs (Soysal et al., 2015) . The respective correlation analysis is currently missing, because tumor RNA was not collected following BC resection in the current study. Future studies, where tumor RNA collection is practically implemented, should shed light on this issue and may dissect the influence of the tumor environment on gene expression of cancer cells and vice versa.
The third critical feature of BC organoids is the possibility to perform functional high-throughput drug screens, as demonstrated earlier for CRC organoids (van de Wetering et al., 2015) . Importantly, drug sensitivities obtained in vitro appear to bear physiological significance as shown here in proof of concept xeno-transplantation assays and recapitulation of the tamoxifen response of metastatic BC patients by derived BC organoid lines. In order to unequivocally translate these findings, organoids should be generated from BC biopsies and treated in parallel to the respective patients in defined clinical trials. Ideally, BC organoids could aid in identifying possible treatment strategies and resistances for individual patients even in the absence of molecular underpinnings. Indeed, CRC organoid drug screens have recently been used to functionally identify resistance mechanisms of targeted therapies (Verissimo et al., 2016) . Correlating histological, genetic, and/ or gene expression data to BC organoid drug responses will further advance our molecular and functional understanding of BC.
In order to share established BC organoid lines and relevant data ethically responsibly with the scientific community, while protecting patient confidentiality and the right to withdraw informed consent, HUB and METC-UMCU implemented a rigorous protocol overseeing biobanking and case-by-case distribution. We already built a living biobank of more than 100 BC organoid lines from a wide variety of primary and metastatic tumors without bias and will continue to do so until we reached a comprehensive BC organoid set representative of all BC subtypes. In conclusion, we propose BC organoids as valuable pre-clinical BC model for academic, clinical, and pharmaceutical research.
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Hans Clevers (h.clevers@hubrecht.eu) . Biobanked organoids will be cataloged at the HUB foundation for Organoid Technology http:// hub4organoids.eu and can be requested at info@hub4organoids.eu. Distribution of organoids to third (academic or commercial) parties requires completion of a material transfer agreement and will have to be authorised by the medical ethical committee UMCU at request of the HUB in order to ensure compliance with the Dutch medical research involving human subjects' act. Use of organoids is subjected to patient consent; upon consent withdrawal, distributed organoid lines and any derived material will have to be promptly disposed of.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Approval of studies involving humans and patient informed consent The collection of BC patient data and tissue for the generation and distribution of BC organoids has been performed according to the guidelines of the European Network of Research Ethics Committees (EUREC) following European, national, and local law (Lanzerath, 2016) . In the Netherlands, the responsible accredited ethical committees reviewed and approved the studies in accordance with the 'Wet medisch-wetenschappelijk onderzoek met mensen' (medical research involving human subjects act) (Borst-Eilers and Sorgdrager, 1998). The medical ethical committee UMC Utrecht (METC UMCU) approved protocol 12-427/C for the establishment of mammary gland organoid cultures as well as biobanking protocol HUB-Cancer TcBio#12-093. In Germany, the legal competence of the research ethical committees is restricted to drug research and to research on medicinal devices (Lanzerath, 2011) . Patients were exclusively recruited in the federal state of Hamburg, Germany where approval of anonymised biomedical research by an ethical committee is not required (Ethik Kommission Ä rztekammer Hamburg, 2015) . All patients participating in the biobank study signed informed consent forms approved by the responsible authority (see above). In all cases, patients can withdraw their consent at any time, leading to the prompt disposal of their tissue and any derived material. Patients participating under protocol 12-427/C did not sign informed consent since derived organoids were not biobanked. Biobanked organoids will be cataloged at http:// hub4organoids.eu and can be requested at info@hub4organoids.eu. Distribution of organoids to third (academic or commercial) parties will have to be authorised by the METC UMCU at request of the HUB in order to ensure compliance with the Dutch medical research involving human subjects' act. Clinical information is available in Table S1 . Age, weight, and height of subjects can be inquired through info@hub4organoids.eu.
BC tissue processing
Upon arrival, BC tissues were photographed and cut into 1-3 mm 3 pieces. Two random pieces were snap frozen and stored at À80 C for DNA isolation, two random pieces were fixed in formalin for histopathological analysis and immunohistochemistry, and the remainder was processed for the isolation of viable cells. The remaining tissue was minced, washed with 10 mL AdDF+++ (Advanced DMEM/F12 containing 1x Glutamax, 10 mM HEPES, and antibiotics) and digested in 10 mL BC organoid medium (Table S2) containing 1-2 mg$ml -1 collagenase (Sigma, C9407) on an orbital shaker at 37 C for 1-2 h. The digested tissue suspension was sequentially sheared using 10 mL and 5 mL plastic and flamed glass Pasteur pipettes. After every shearing step the suspension was strained over a 100 mm filter with retained tissue pieces entering a subsequent shearing step with $10ml AdDF+++. 2% FCS were added to the strained suspension before centrifugation at 400 rcf. The pellet was resuspended in 10ml AdDF+++ and centrifuged again at 400 rcf. In case of a visible red pellet, erythrocytes were lysed in 2 mL red blood cell lysis buffer (Roche, 11814389001) for 5 min at room temperature before the addition of 10ml AdDF+++ and centrifugation at 400 rcf. Needle biopsies of metastatic BC lesions were processed as above following removal of macroscopically obvious non tumor tissue (e.g., liver).
BC organoid culture
The pellet was resuspended in 10 mg$ml -1 cold Cultrex growth factor reduced BME type 2 (Trevigen, 3533-010-02) and 40 mL drops of BME-cell suspension were allowed to solidify on prewarmed 24-well suspension culture plates (Greiner, M9312) at 37 C for 20 min. Upon completed gelation, 400 mL of BC organoid medium (Table S2 ) was added to each well and plates transferred to humidified 37 C / 5% CO 2 incubators at either 2% or ambient O 2 . Medium was changed every 4 days and organoids were passaged every 1-4 weeks: cystic organoids were resuspended in 2 mL cold AdDF+++ and mechanically sheared through flamed glass Pasteur pipettes. Dense organoids were dissociated by resuspension in 2 mL TrypLE Express (Invitrogen, 12605036), incubation for 1-5 min at room temperature, and mechanical shearing through flamed glass Pasteur pipettes. Following the addition of 10 mL AdDF+++ and centrifugation at 300 rcf. or 400 rcf. respectively, organoid fragments were resuspended in cold BME and reseeded as above at ratios (1:1 to 1:6) allowing the formation of new organoids. Single cell suspensions were initially seeded at high density and reseeded at a lower density after $1 week. In order to prevent misidentification and/or cross-contamination of BC organoids, we cultured every line physically separate, implemented the use of a laboratory management system, and validated the identity of biobanked organoid lines by single-nucleotide polymorphism (SNP) based fingerprinting. All organoid lines tested negative in the MycoAlert mycoplasma detection kit (Lonza, LT07-318).
Xeno-transplantations
Organoids were split, strained < 70 mm, and allowed to grow for 5-7 days. Organoids were harvested and injected into the fourth mammary fat pads of NMRI-Nude mice (Charles Rivers) at 10 6 cells in 40 mL of complete BC organoid medium/BME (1:1). Mice with established tumors (average volume of approx. 50 mm 3 ) were treated with vehicle or afatinib (12.5 mg$kg -1 , orally, 5 days on, 2 days off) for 4 weeks. Animals were sacrificed with CO 2 before combined tumors reached a volume of 1,500 mm 3 . For in vivo dosing, afatinib was dissolved in 1.8% hydroxypropyl-b-cyclodextrin (Sigma), 5% of a 10% acetic acid stock, and 0.5% aqueous natrosol. Mammary tumor size was determined 3 times a week by caliper measurements (length and width in mm), and tumor volume (in mm 3 ) was calculated by using the following formula: 0.5 $ length $ width 2 . Data is expressed as the 7 day moving average of these measurements. This study was approved by the Animal Ethics Committee of the Netherlands Cancer Institute (DEC-NKI; OZP = 12012, WP5720), complying with Dutch legislation.
METHOD DETAILS Histology and imaging
Tissue and organoids were fixed in 4% paraformaldehyde followed by dehydration, paraffin embedding, sectioning, and standard HE staining. Sections were randomized and blindly analyzed by a breast cancer pathologist. Immunohistochemistry was performed using antibodies against ERa (Abcam, ab27595, 1:5), PR (DAKO, M3569, 1:150), and HER2 (Thermo, RM-9103-S1, 1:100). Images were acquired on a Leica Eclipse E600 microscope and processed using the Adobe Creative Cloud software package. Time lapse bright-field imaging was performed on a Leica AF7000 fluorescence microscope equipped with a Leica DFC420C camera at 37 C and 5% humidified CO 2 .
Genomic analysis
For karyotyping, 0.1 mg$ml -1 colcemid (GIBCO, 152120-12) was added to the medium of expanding organoids. The following day
Following electroporation, 300ml of complete growth medium was added to the cells and they were incubated in room temperature for 15 minutes. Cells were centrifuged, suspended in 200ml BME and plated as previously described. Complete medium was added after cell-BME suspension drops had solidified. 2-3 days after electroporation 10 mM Nutlin-3 (Cayman Chemical) was added to the growth medium. 2-3 weeks after electroporation, single organoids were picked and transferred into 1.5ml microcentrifuge tubes containing 200 mL of pre-warmed Accutase. Following 2-3 minutes incubation, organoids were sheared into small cell clumps by 0 . Products were cloned into pGEM-T Easy vector system I (Promega) and sequenced using T7 sequencing primer. Three clonal TP53 mutant lines were generated. See also Figure S4 .
Drug screen
Organoids were split, strained < 70 mm, and allowed to grow for 5-7 days. Organoids were harvested and diluted to 75 organoids/ml in growth medium containing 5% BME. Using a Multidrop combi reagent dispenser (ThermoFisher) black, clear bottom 384-well plates (Corning) were coated with 10 mL BME before the addition of 30 mL organoid suspension. Then, 21 concentrations of afatinib, gefitinib, pictilisib, GDC-0068, AZD8055, everolimus (all Selleckchem), or tamoxifen (Sigma) as well as DMSO controls were added in duplicate using a Tecan D300e digital dispenser (Life Sciences). To measure ATP as proxy for viable cells, 40 mL of CellTiter-Glo 3D Reagent (Promega) per well were added after five days, before shaking the plate for 30 min at room temperature and reading luminescence on a SpectraMax microplate reader (Molecular Devices). Data was analyzed using GraphPad Prism 6 followed by manual determination of IC 50 values (absolute for homogeneous populations, relative for heterogeneous populations). Averages of IC 50 s from two to three independent experiments were calculated and visualized using Morpheus (https://software.broadinstitute. org/morpheus) and CorelDraw X7. For the PARPi assay, organoids were harvested 2-4 days post-seeding, strained < 100 mm, diluted to a concentration of 13-20 organoids/ml in BME and replated in 48 well plates (20 mL of BME per well). Organoids were grown for 2 weeks at the indicated concentrations of olaparib and niraparib in BC medium lacking N-Acetylcysteine and Y-27632. Medium was removed and BME drops were suspended in 100 mL CellTiter-Glo 3D and 80 mL advanced DMEM/F12. Following transfer to 96well black U-shaped plates (Greiner), 5 min shaking and 15 min incubation at RT, luminescence was measured in a plate reader (Centro LB960). Each condition was tested in replicates and results were normalized to the lowest concentration with values R DMSO controls.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical methods are outlined in the respective figure legends were applicable. Statistical analyses were performed with MS Excel and Prism GraphPad. P values were calculated using two-tailed Student's t test assuming a normal sample distribution. Sample size for animal experiments was determined based upon pilot experiments. Investigators were blinded for evaluation of all tissue stainings. Data shown are either representative of two or more independent experiments or combined from two or more independent experiments as indicated. Data is analyzed as mean ± SEM. Sequence analysis details can be found in the respective STAR Methods sections.
DATA AND SOFTWARE AVAILABILITY
Illumina data processing pipeline v2.2.1 is available under https://github.com/UMCUGenetics/IAP/releases/tag/v2.2.1, RNA analysis pipeline v2.1.0 is available under https://github.com/UMCUGenetics/RNASeq. Details for the detection of somatic mutations can be found under https://github.com/UMCUGenetics/IAP/blob/v2.2.1/settings/CPCT.ini. Deleterious variants were identified using https://github.com/UMCUGenetics/SmallTools/blob/master/Make_Somatic_Mutation_Overview.py. BAM files for DNA and RNA sequencing data are made available through controlled access at the European Genome-phenome Archive (EGA) which is hosted at the EBI and the CRG (https://ega-archive.org), under accession number EGA: EGAS00001002158. Data access requests will be evaluated by the UMCU Department of Genetics Data Access Board (EGAC00001000432) and transferred upon completion of a material transfer agreement and authorization by the medical ethical committee UMCU at request of the HUB in order to ensure compliance with the Dutch 'medical research involving human subjects' act. 
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